CD44 Antibodies and Immune Thrombocytopenia in the Amelioration of Murine Inflammatory Arthritis
Open Access
- 13 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6), e65805
- https://doi.org/10.1371/journal.pone.0065805
Abstract
Antibodies to CD44 have been used to successfully ameliorate murine models of autoimmune disease. The most often studied disease model has been murine inflammatory arthritis, where a clear mechanism for the efficacy of CD44 antibodies has not been established. We have recently shown in a murine passive-model of the autoimmune disease immune thrombocytopenia (ITP) that some CD44 antibodies themselves can induce thrombocytopenia in mice, and the CD44 antibody causing the most severe thrombocytopenia (IM7), also is known to be highly effective in ameliorating murine models of arthritis. Recent work in the K/BxN serum-induced model of arthritis demonstrated that antibody-induced thrombocytopenia reduced arthritis, causing us to question whether CD44 antibodies might primarily ameliorate arthritis through their thrombocytopenic effect. We evaluated IM7, IRAWB14.4, 5035-41.1D, KM201, KM114, and KM81, and found that while all could induce thrombocytopenia, the degree of protection against serum-induced arthritis was not closely related to the length or severity of the thrombocytopenia. CD44 antibody treatment was also able to reverse established inflammation, while thrombocytopenia induced by an anti-platelet antibody targeting the GPIIbIIIa platelet antigen, could not mediate this effect. While CD44 antibody-induced thrombocytopenia may contribute to some of its therapeutic effect against the initiation of arthritis, for established disease there are likely other mechanisms contributing to its efficacy. Humans are not known to express CD44 on platelets, and are therefore unlikely to develop thrombocytopenia after CD44 antibody treatment. An understanding of the relationship between arthritis, thrombocytopenia, and CD44 antibody treatment remains critical for continued development of CD44 antibody therapeutics.Keywords
This publication has 48 references indexed in Scilit:
- Platelets: active players in the pathogenesis of arthritis and SLENature Reviews Rheumatology, 2012
- Platelets Participate in Synovitis via Cox-1–Dependent Synthesis of Prostacyclin Independently of Microparticle GenerationThe Journal of Immunology, 2011
- Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle ProductionScience, 2010
- CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritisBlood, 2008
- Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoidsThe Journal of Experimental Medicine, 2008
- Cells of the synovium in rheumatoid arthritis. MacrophagesArthritis Research & Therapy, 2007
- Monoclonal antibodies to CD44 and their influence on hyaluronan recognition.The Journal of cell biology, 1995
- Hyaluronate receptors: key players in growth, differentiation, migration and tumor progressionCurrent Opinion in Cell Biology, 1994
- The importance of the t cell in initiating and maintaining the chronic synovitis of rheumatoid arthritisArthritis & Rheumatism, 1992
- Production of agglutinators and rheumatoid factors in plasma cells of rheumatoid and nonrheumatoid synovial tissuesArthritis & Rheumatism, 1981